AN ADVISORY committee at the US Food and Drug Administration has voted to recommend an RSV vaccine for pregnant women in their third trimester, to help prevent RSV (respiratory syncytial virus) infections in infants from birth up to six months of age.
Pfizer has submitted the results from a phase 3 trial of a candidate immunisation involving 650 healthy pregnant women, which found an efficacy of 81.8% in the prevention of RSV.
Annaliesa Anderson, Pfizer Chief Scientific Officer of Vaccine R&D, welcomed the recommendation, saying "if approved, our RSV vaccine candidate has the potential to be the first maternal immunisation vaccine to help protect infants at first breath through their first six months of life from this potentially serious infection".
The above article was sent to subscribers in Pharmacy Daily's issue from 24 May 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 May 23
